###begin article-title 0
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
Activation of Mutant Enzyme Function In Vivo by Proteasome Inhibitors and Treatments that Induce Hsp70
###end article-title 0
###begin p 1
Conceived and designed the experiments: LRS WDK. Performed the experiments: LRS SG NHH. Analyzed the data: LRS SG. Contributed reagents/materials/analysis tools: JPK. Wrote the paper: WDK.
###end p 1
###begin p 2
###xml 619 643 613 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Saccharomyces cerevisiae</italic>
###xml 1022 1035 1016 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S. cerevisiae</italic>
###xml 209 214 <span type="species:ncbi:4932">yeast</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
###xml 619 643 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 918 923 <span type="species:ncbi:9606">human</span>
###xml 1022 1035 <span type="species:ncbi:4932">S. cerevisiae</span>
###xml 1177 1185 <span type="species:ncbi:9606">patients</span>
###xml 1195 1200 <span type="species:ncbi:10090">mouse</span>
###xml 1241 1246 <span type="species:ncbi:9606">human</span>
Missense mutant proteins, such as those produced in individuals with genetic diseases, are often misfolded and subject to processing by intracellular quality control systems. Previously, we have shown using a yeast system that enzymatic function could be restored to I278T cystathionine beta-synthase (CBS), a cause of homocystinuria, by treatments that affect the intracellular chaperone environment. Here, we extend these studies and show that it is possible to restore significant levels of enzyme activity to 17 of 18 (94%) disease causing missense mutations in human cystathionine beta-synthase (CBS) expressed in Saccharomyces cerevisiae by exposure to ethanol, proteasome inhibitors, or deletion of the Hsp26 small heat shock protein. All three of these treatments induce Hsp70, which is necessary but not sufficient for rescue. In addition to CBS, these same treatments can rescue disease-causing mutations in human p53 and the methylene tetrahydrofolate reductase gene. These findings do not appear restricted to S. cerevisiae, as proteasome inhibitors can restore significant CBS enzymatic activity to CBS alleles expressed in fibroblasts derived from homocystinuric patients and in a mouse model for homocystinuria that expresses human I278T CBS. These findings suggest that proteasome inhibitors and other Hsp70 inducing agents may be useful in the treatment of a variety of genetic diseases caused by missense mutations.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 454 457 454 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CBS</italic>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 613 618 <span type="species:ncbi:9606">human</span>
###xml 1130 1135 <span type="species:ncbi:9606">human</span>
Genetic diseases are often caused by missense mutations: single nucleotide changes that cause a single incorrect amino acid to be substituted into the underlying protein. Most missense mutations cause the encoded protein to fold incorrectly and therefore not function properly. Examples of missense mutation diseases include CBS deficiency, Li-Fraumeni syndrome, and methylenetetrahydrofolate reductase deficiency, which are caused by alterations in the CBS, TP53, and MTHFR genes, respectively. In the work presented here, we show that it is possible to restore substantial enzymatic function to disease-causing human mutant CBS, p53, and MTHFR proteins by treatments that alter the intracellular folding environment. All of these treatments result in elevation of the Hsp70 protein, a molecular chaperone protein involved in helping proteins fold properly. One way to rescue mutant protein function is by using a drug that inhibits the function of the proteasome, the intracellular machine responsible for degrading misfolded proteins. Our findings suggest that drugs of this class may be potentially useful in the treatment of human genetic diseases caused by missense mutations.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Stenson1">[1]</xref>
###xml 612 615 612 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Bross1">[2]</xref>
Missense mutations are genetic alterations that result in the production of proteins with single amino acid changes and are an especially common cause of a variety of diseases [1]. Most disease causing missense mutations do not target key catalytic residues, but rather cause problems in protein folding. It is thought that missense mutations affect protein folding by "trapping" the protein in a non-functional intermediate state, preventing it from folding into its lowest-free energy native state. These trapped misfolded protein intermediates can either be degraded or form large molecular weight aggregates [2]. In theory, treatments that could reverse these protein-folding defects and promote proper folding would be of great utility in the treatment of a wide variety of genetic diseases.
###end p 6
###begin p 7
###xml 426 433 423 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 617 620 606 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Kruger1">[3]</xref>
###xml 761 764 750 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Mudd1">[4]</xref>
###xml 1140 1143 1129 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Wilcken1">[5]</xref>
###xml 1144 1147 1133 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Yap1">[6]</xref>
###xml 1148 1151 1137 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Yap2">[7]</xref>
###xml 1353 1356 1342 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Gupta1">[8]</xref>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
###xml 804 812 <span type="species:ncbi:9606">patients</span>
###xml 1000 1008 <span type="species:ncbi:9606">patients</span>
###xml 1153 1158 <span type="species:ncbi:10090">Mouse</span>
Three genetic diseases in which missense mutations are common include cystathionine beta-synthase (CBS) deficiency, Li Fraumeni syndrome, and methylenetetrahydrofolate reductase deficiency. CBS deficiency is an inborn error of sulfur metabolism characterized by very high levels of plasma total homocysteine (tHcy). CBS catalyzes the condensation of homocysteine with serine to form cystathionine and is the first step in the de novo production of cysteine. In healthy adults, tHcy concentration in plasma ranges from 5 to 15 microM, but untreated patients with CBS deficiency often have tHcy in excess of 200 microM [3]. CBS deficient patients suffer from various pathologies including arteriosclerosis, osteoporosis, mental retardation, and dislocated lenses [4]. The major cause of mortality in these patients is stroke. Treatments that lower tHcy such as B-vitamins, dietary methionine restriction, and betaine supplementation, can significantly reduce the incidences of vascular events in these patients despite the fact that post-treatment homocysteine levels are still several times higher than levels found in the normal population [5],[6],[7]. Mouse models for CBS deficiency also indicate that there is a threshold effect for tHcy toxicity and support the notion that a small increase in residual CBS activity may have large clinical benefits [8].
###end p 7
###begin p 8
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 138 141 138 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Varley1">[9]</xref>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Gonzalez1">[10]</xref>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 556 560 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Esrig1">[11]</xref>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 646 650 646 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-CooperEVB1">[12]</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 617 622 <span type="species:ncbi:9606">Human</span>
Li-Fraumeni syndrome is a dominant cancer susceptibility syndrome disorder caused by missense mutations in the TP53 tumor suppressor gene [9]. Li-Fraumeni patients suffer from a variety of cancers, including sarcomas, adrenocorticol carcinomas, breast cancer, leukemia, and brain tumors [10]. In general, TP53 behaves as a classic tumor suppressor gene, with the tumors losing or inactivating the wild-type copy of TP53, resulting in expression of only the mutant form. Mutant forms of p53 tend to be stable, resulting in increased accumulation of protein [11]. Of the 165 mutations in the TP53 gene described in the Human Gene Mutation Database [12], 110 are of the missense variety (68%).
###end p 8
###begin p 9
###xml 269 274 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTHFR</italic>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Goyette1">[13]</xref>
###xml 570 574 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-CooperEVB1">[12]</xref>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
MTHFR is a critical enzyme in the remethylation of homocysteine to methionine. Its biochemical function is to catalyze the formation of 5-methyltetrahydrofolate, which is the methyl-group donor for the subsequent reaction catalyzed by methionine synthase. Mutations in MTHFR are known to cause MTHFR deficiency. MTHFR deficiency symptoms include developmental delay, motor or gait abnormalities, seizures, and premature vascular disease [13]. Thirty-four mutations have been described in MTHFR deficient patients, and 23 are predicted to encode missense mutations (67%) [12].
###end p 9
###begin p 10
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Young1">[15]</xref>
###xml 513 517 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Hartl1">[16]</xref>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 877 882 <span type="species:ncbi:9606">human</span>
###xml 898 903 <span type="species:ncbi:10090">mouse</span>
Previously, work from our lab has shown that it is possible to restore significant enzymatic function to human CBS containing an isoleucine to threonine substitution at position 278 (I278T) by growth of cells in ethanol containing media [14]. This rescue was shown to require the induction of Hsp70, a key cellular chaperone protein [15]. Hsp70 protein interacts with misfolded polypeptides along with co-chaperones and promotes refolding by repeated cycles of binding and release requiring the hydrolysis of ATP [16]. In the work described here, we have extended our observations by showing that treatments that induce Hsp70 can greatly increase enzymatic function from 17 additional mutant CBS proteins, as well as mutant forms of p53 and MTHFR. In addition we show that proteasome inhibitors can induce Hsp70 and that these drugs can greatly increase mutant CBS activity in human cells and in a mouse model of CBS deficiency. Our findings support the idea that drugs that induce Hsp70 may be useful in the treatment of genetic disorders caused by missense mutations.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP26</italic>
###xml 68 73 <span type="species:ncbi:9606">human</span>
Ethanol and deletion of HSP26 restores enzymatic activity to mutant human CBS
###end title 12
###begin p 13
###xml 81 84 81 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CBS</italic>
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Kraus1">[17]</xref>
###xml 232 235 232 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CBS</italic>
###xml 242 251 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cys4&#916;</italic>
###xml 341 350 337 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g001">Figure 1A</xref>
###xml 584 600 580 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g001">Figure 1B and 1C</xref>
###xml 602 603 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s001">1</xref>
###xml 605 612 601 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000807-t001">Table 1</xref>
###xml 1094 1103 1090 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g001">Figure 1B</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 177 182 <span type="species:ncbi:4932">yeast</span>
We initially examined the effect of ethanol on a panel of 17 additional missense CBS mutations found in homocystinuric patients [17]. Each of these mutations was expressed in a yeast strain (WY35) that is deleted for the endogenous CBS gene (cys4Delta) and growth was examined on cysteine-free media either lacking or containing 4% ethanol (Figure 1A). In addition, we prepared total cellular lysates from the strains grown in cysteine-supplemented media with or without ethanol and measured both the steady state level of each mutant protein by Western blot and CBS enzyme activity (Figure 1B and 1C, 1, Table 1). We found that 4/17 (24%) of the mutants exhibited significant growth and greatly increased CBS enzyme activity (8 to 50-fold) when grown in ethanol-containing media. Interestingly, like I278T, ethanol had a much more modest effect on steady state protein levels compared to enzyme activity, indicating that the treatment caused the specific activity of the enzyme to increase. Ethanol exposure also increased steady state Hsp70 levels, consistent with our previous observations (Figure 1B).
###end p 13
###begin title 14
###xml 47 57 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp26&#916;</italic>
Functional rescue of mutant CBS by ethanol and hsp26Delta.
###end title 14
###begin p 15
###xml 599 604 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP26</italic>
###xml 615 625 609 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp26&#916;</italic>
###xml 718 728 708 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp26&#916;</italic>
###xml 885 890 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hsp26</italic>
###xml 34 39 <span type="species:ncbi:4932">yeast</span>
###xml 41 45 <span type="species:ncbi:4932">WY35</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 606 610 <span type="species:ncbi:4932">WY35</span>
###xml 632 637 <span type="species:ncbi:4932">yeast</span>
(A) A stationary phase culture of yeast (WY35) transformed with a plasmid expressing the indicated human CBS allele was diluted 1:1000 in SC-Cys media with or without 4% ethanol and grown at 30degreesC for 24 h. Growth was determined by measuring OD at 600 nm. (B). Western analysis of two representative ethanol rescuable (T353M, T262M) and two non-rescuable (G307S, D376N) mutants. Cells were grown in SC+CYS media with or without ethanol and extracts were probed with indicated antibody. (C) CBS enzyme activity of each of the mutant alleles in the presence and absence of ethanol. (D) Growth of HSP26 (WY35) or hsp26Delta (LS2) yeast expressing the indicated CBS allele. (E) Western analysis of two representative hsp26Delta rescuable (T353M, A231L) and two non-rescuable (T191M, L101P) mutants. (F) CBS enzyme activity of each of the mutant alleles in the presence and absence of Hsp26.
###end p 15
###begin title 16
###xml 58 63 <span type="species:ncbi:4932">yeast</span>
Relative levels are shown for CBS protein and activity in yeast.
###end title 16
###begin p 17
###xml 0 94 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Protein is normalized to 1 while enzyme activity is normalized to 100 for wild-type human CBS.</bold>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Protein is normalized to 1 while enzyme activity is normalized to 100 for wild-type human CBS.
###end p 17
###begin p 18
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP26</italic>
###xml 83 93 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp26&#916;</italic>
###xml 176 180 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 255 275 251 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cys4&#916; hsp26&#916;</italic>
###xml 337 347 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp26&#916;</italic>
###xml 400 409 384 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g001">Figure 1E</xref>
###xml 424 429 408 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hsp26</italic>
###xml 565 577 549 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g001">Figure 1D&#8211;1F</xref>
###xml 579 588 563 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s002">Figure S2</xref>
###xml 590 597 574 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000807-t001">Table 1</xref>
###xml 170 175 <span type="species:ncbi:4932">yeast</span>
Previously, we had also shown that deletion of the small heat shock protein HSP26 (hsp26Delta) could effectively suppress the functional effects of I278T CBS mutation in yeast [14]. Therefore, we introduced our panel of additional missense mutants into a cys4Delta hsp26Delta double mutant strain and examined function. As with ethanol, hsp26Delta resulted in increased steady state levels of Hsp70 (Figure 1E). Deletion of Hsp26 could rescue the cysteine growth auxotrophy and restore significant levels of enzymatic activity to 10/17 (59%) of the mutants tested (Figure 1D-1F, Figure S2, Table 1). Again, the increased level of enzyme activity in the suppressible mutants was impressive, ranging from an 8 to 55-fold increase resulting in levels that were between 25% and 58% of wild-type CBS. Like ethanol, most of the increased enzyme activity appears to be due to increased functionality of the mutant protein as opposed in increased protein levels.
###end p 18
###begin p 19
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 355 364 355 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s003">Figure S3</xref>
In our earlier work, we had shown that expression of I278T CBS drove down levels of Hsp26 protein and that I278T CBS, but not wild-type CBS, physically interacted with Hsp26 [14]. We tested two of the newer mutants (G307S, D376N) for these properties and found that they also caused decreased steady state levels of Hsp26 and co-immunoprecipitated Hsp26 (Figure S3). These results indicate that like I278T, G307S and D376N form a complex with Hsp26.
###end p 19
###begin title 20
###xml 66 79 66 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S. cerevisiae</italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 66 79 <span type="species:ncbi:4932">S. cerevisiae</span>
Bortezomib rescues several forms of mutant human CBS expressed in S. cerevisiae
###end title 20
###begin p 21
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Lee1">[18]</xref>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Kim1">[19]</xref>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Orlowski1">[20]</xref>
###xml 642 651 642 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g002">Figure 2A</xref>
###xml 1077 1086 1073 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g002">Figure 2B</xref>
###xml 79 84 <span type="species:ncbi:4932">yeast</span>
###xml 327 333 <span type="species:ncbi:9606">humans</span>
###xml 414 419 <span type="species:ncbi:9606">human</span>
###xml 442 447 <span type="species:ncbi:4932">yeast</span>
###xml 489 494 <span type="species:ncbi:4932">yeast</span>
###xml 575 579 <span type="species:ncbi:4932">WY35</span>
###xml 616 621 <span type="species:ncbi:9606">human</span>
###xml 766 770 <span type="species:ncbi:4932">WY35</span>
###xml 792 797 <span type="species:ncbi:9606">human</span>
###xml 1190 1195 <span type="species:ncbi:4932">yeast</span>
Since proteasome inhibitors have previously been shown to induce Hsp70 in both yeast and mammalian cells [18],[19], we tested if these agents might be able to restore function to missense mutant CBS proteins in vivo. Bortezomib (also known as PS-341 or Velcade) is a potent proteasome inhibitor that is currently used to treat humans with multiple myeloma [20]. We first tested the effects of bortezomib on mutant human I278T CBS function in yeast. We found that addition of bortezomib to yeast media strongly rescued, in a dose-dependent fashion, the cysteine auxotrophy of WY35 cells carrying a plasmid expressing human I278T CBS (pI278T) (Figure 2A). After 24 hours, 75 microM bortezomib allowed WY35pI278T cells to achieve growth that was at least equivalent to WY35 expressing wild type human CBS (phCBS). Examination of I278T protein and activity from treated vs. untreated cells indicated that bortezomib increased steady-state levels of I278T by 7-fold and increased I278T activity by 27-fold, to about 50% of that observed in untreated cells expressing wild-type CBS (Figure 2B). These results show that bortezomib can both stabilize and restore function to I278T CBS expressed in yeast.
###end p 21
###begin title 22
###xml 51 64 51 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S. cerevisiae</italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 51 64 <span type="species:ncbi:4932">S. cerevisiae</span>
Functional rescue of mutant human CBS expressed in S. cerevisiae by bortezomib treatment.
###end title 22
###begin p 23
###xml 532 553 518 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1006 1009 982 985 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 34 39 <span type="species:ncbi:4932">yeast</span>
###xml 41 45 <span type="species:ncbi:4932">WY35</span>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 293 297 <span type="species:ncbi:4932">WY35</span>
###xml 309 313 <span type="species:ncbi:4932">WY35</span>
###xml 615 620 <span type="species:ncbi:4932">Yeast</span>
###xml 628 632 <span type="species:ncbi:4932">WY35</span>
###xml 640 644 <span type="species:ncbi:4932">WY35</span>
###xml 836 841 <span type="species:ncbi:4932">yeast</span>
###xml 849 853 <span type="species:ncbi:4932">WY35</span>
###xml 1062 1066 <span type="species:ncbi:4932">WY35</span>
(A) A stationary phase culture of yeast (WY35) transformed with a plasmid expressing either WT (phCBS) or I278T (pI278T) human CBS was diluted 1:1000 in SC-Cys media with the indicated amount of bortezomib and grown at 30degreesC for 24 h. Growth was determined by measuring OD at 600 nm. (B) WY35 pI278T and WY35 phCBS cells were grown in SC-Trp+Cys media either with or without 50 microM of bortezomib for 24 hours and extracts were prepared. Levels of CBS, alpha-tubulin, and Hsp70 and CBS activity were assessed as described in Materials and Methods. CBS units are nmole cystathionine formed/mg protein-hr. (C) Yeast strain WY35 phCBS, WY35 pI278T, LS3 phCBS, LS3 pI278T were grown at 30degreesC in the absence and presence of bortezomib and extracts were assessed for CBS activity and CBS protein. (D) Stationary phase cultures of yeast strain WY35 expressing the indicated allele of CBS were diluted 1:1000 in SC-Cys media either with or without 50 microM of bortezomib and growth was monitored by OD600 after 24 h at 30degreesC. (E) Log phase cultures of WY35 grown in SC+Cys media with or without 50 microM of bortezomib expressing the indicated CBS allele were harvested, lystates prepared, and CBS enzyme activity was measured and expressed in units.
###end p 23
###begin p 24
###xml 119 128 119 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g002">Figure 2B</xref>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSA2</italic>
###xml 299 308 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ssa2&#916;</italic>
###xml 310 319 306 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g002">Figure 2C</xref>
###xml 430 434 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSA2</italic>
###xml 439 448 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ssa2&#916;</italic>
###xml 557 566 549 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ssa2&#916;</italic>
###xml 613 622 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ssa2&#916;</italic>
###xml 716 720 700 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSA2</italic>
###xml 905 909 889 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSA2</italic>
###xml 255 260 <span type="species:ncbi:4932">yeast</span>
###xml 751 756 <span type="species:ncbi:9606">human</span>
Bortezomib treatment also caused a 2.8 to 3.6-fold increase in Hsp70 in WT and I278T expressing strains, respectively (Figure 2B). To determine if this induction was essential for restoration of I278T CBS function, we examined the effect of bortezomib on yeast lacking the Hsp70-encoding gene SSA2 (ssa2Delta; Figure 2C). As expected, steady state levels and the enzyme activity of I278T CBS were lower compared to wt CBS in both SSA2 and ssa2Delta cells in the absence of bortezomib. In the presence of bortezomib, we saw stabilization of I278T protein in ssa2Delta cells, but no increase in enzyme activity. In ssa2Delta cells expressing WT CBS, we did not observe any decrease in enzyme activity, indicating that SSA2 is not required generally for human CBS function. These results show that simply blocking proteolysis of I278T CBS is not sufficient to restore function to the mutant enzyme, and that SSA2 (Hsp70 protein) is required for bortezomib-induced rescue of function.
###end p 24
###begin p 25
###xml 256 265 256 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g002">Figure 2D</xref>
###xml 471 480 471 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s004">Figure S4</xref>
###xml 68 75 <span type="species:ncbi:9606">patient</span>
We also investigated the effect of bortezomib on our panel of other patient-derived CBS mutants. We found that 9/17 of the alleles tested showed significant growth in cysteine-free media and had enzyme activity restored to between 37-68% of wild-type CBS (Figure 2D). It should be noted that some of these mutants (T353M and T262M for example) produce stable but non-functional enzymes, indicating that bortezomib is not simply working by preventing protein degradation (Figure S4)
###end p 25
###begin title 26
Restoration of function to mutant forms of p53 and MTHFR
###end title 26
###begin p 27
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADE2</italic>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Flaman1">[21]</xref>
###xml 727 736 727 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g003">Figure 3A</xref>
###xml 832 842 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp26&#916;</italic>
###xml 159 164 <span type="species:ncbi:4932">yeast</span>
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 401 406 <span type="species:ncbi:9606">human</span>
###xml 437 444 <span type="species:ncbi:9606">patient</span>
###xml 622 627 <span type="species:ncbi:9606">human</span>
We next determined if chaperone manipulation could be used to restore function to disease causing mutants of p53 and MTHFR. To examine p53 function, we used a yeast strain (yIG397) in which human p53 binds upstream of the ADE2 promoter, activates transcription, and results in correction of the strains adenine auxotrophy [21]. Into this strain we transfected plasmids that expressed either wild-type human p53 or one of three different patient-identified point mutations (R175H, R273H, C277F) and measured p53 function by examining growth in adenine deficient media. As expected, we found that cells expressing wild type human p53 grew well, while cells expressing the mutant alleles had almost undetectable levels of growth (Figure 3A). However, when the media was supplemented with either 4% ethanol, 50 microM Bortezomib, or an hsp26Delta construct was introduced into the strain, each mutant exhibited significant growth rescue with at least one of the treatments.
###end p 27
###begin title 28
###xml 45 50 <span type="species:ncbi:4932">yeast</span>
Functional rescue of mutant p53 and MTHFR in yeast.
###end title 28
###begin p 29
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP26</italic>
###xml 952 962 938 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">met11&#916;</italic>
###xml 4 9 <span type="species:ncbi:4932">Yeast</span>
###xml 175 180 <span type="species:ncbi:4932">yeast</span>
###xml 412 417 <span type="species:ncbi:4932">Yeast</span>
###xml 610 615 <span type="species:ncbi:4932">Yeast</span>
###xml 917 922 <span type="species:ncbi:4932">Yeast</span>
(A) Yeast p53 tester strain yIG397 (HSP26), or LS2 (hsp26Delta) were transformed with an expression plasmid expressing the indicated p53 alleles. Stationary phase cultures of yeast expressing the wild type and indicated mutant were diluted 1:1000 in SC-ura -ade media grown in 15 ml tubes with aeration at 30degreesC for 24 hours. Where indicated, 4% ethanol or 50 microM bortezomib were added to the media. (B) Yeast strain yIG397 carrying the indicated p53 alleles was grown in adenine containing media with or without 4% ethanol. Lysates were then probed by Western Blot with the indicated anti-bodies. (C) Yeast strains yIG397 and LS2 expressing the indicated p53 alleles were grown in adenine containing media supplemented with 4% ethanol when indicated. Lysates were prepared and immunoprecipitation was performed with anti-p53 antibody and Hsp26 present in the immune complexes was analyzed by immunoblot. (D) Yeast MTHFR tester strain XSY3-1A (met11Delta) were transformed with expression plasmids expressing the indicated MTHFR allele.
###end p 29
###begin p 30
###xml 280 289 280 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g003">Figure 3B</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
We performed more in depth analysis on two of the mutant alleles, R175H and R273H. In the absence of ethanol, steady state levels of both of these mutant proteins are slightly elevated compared to wild type CBS and cause elevations in the steady state levels of Hsp26 and Hsp104 (Figure 3B). The elevation in Hsp104 was unexpected, as we had previously shown that I278T CBS had no effect on Hsp104 levels [14]. When ethanol is added to the cultures, Hsp70 levels are induced and p53 and Hsp26 levels are reduced to wild-type levels, while hsp104 levels remain elevated. The observation that p53 levels go down, while growth increases indicates that, like CBS, ethanol is enhancing the specific activity of p53.
###end p 30
###begin p 31
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSA2</italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP104</italic>
###xml 99 108 99 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s005">Figure S5</xref>
###xml 405 414 405 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g003">Figure 3C</xref>
We also examined the dependence of ethanol rescue on having a functionally intact SSA2 and HSP104 (Figure S5). Deletion of either gene resulted in total loss of the ability of ethanol to promote adenine independent growth. Immunoprecipitation experiments demonstrate that, similar to mutant CBS, Hsp26 recognizes mutant p53 but not wild-type p53 and that this interaction is lost upon ethanol treatment. (Figure 3C). Taken together, these results show that p53 mutants behave similar, but not identical, to CBS mutants with regards to rescue by agents that perturb the cellular chaperone environment.
###end p 31
###begin p 32
###xml 261 282 261 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 625 634 625 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s006">Figure S6</xref>
###xml 246 251 <span type="species:ncbi:9606">human</span>
We next determined the frequency by which defective p53 protein could be rescued by either ethanol or bortezomib treatment. We examined rescue using a panel of 22 single missense mutant p53 alleles that were obtained by random mutagenesis of the human p53 (see Materials and Methods). Like CBS, we found that some mutants were rescuable by both ethanol and bortezomib (4/22), some only by bortezomib (8/22), some only by ethanol (4/22), and some that were not rescuable by either treatment (6/22). In total, we found that 16 out of 22 (72%) of the randomly generated mutants were rescuable by at least one of the treatments (Figure S6).
###end p 32
###begin p 33
###xml 268 278 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">met11&#916;</italic>
###xml 286 290 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Shan1">[22]</xref>
###xml 476 485 472 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g003">Figure 3D</xref>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 149 154 <span type="species:ncbi:4932">yeast</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
We have also examined the effect of ethanol and bortezomib on mutant alleles of human 5-10-methylene tetrahydrofolate reductase (MTHFR) expressed in yeast. In this assay, expression of a functional human MTHFR enzyme complements the methionine auxotrophy present in a met11Delta mutant [22]. Two missense mutant MTHFR proteins were tested for growth rescue by either addition of ethanol or bortezomib and we found that one, L323P, could be rescued by the addition of ethanol (Figure 3D).
###end p 33
###begin title 34
###xml 31 38 <span type="species:ncbi:9606">patient</span>
Restoration of CBS function in patient fibroblasts by MG132
###end title 34
###begin p 35
###xml 65 78 65 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S. cerevisiae</italic>
###xml 684 693 684 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g004">Figure 4A</xref>
###xml 823 832 823 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s007">Figure S7</xref>
###xml 1636 1645 1636 1645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g004">Figure 4A</xref>
###xml 65 78 <span type="species:ncbi:4932">S. cerevisiae</span>
###xml 215 220 <span type="species:ncbi:9606">human</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 1027 1032 <span type="species:ncbi:9606">human</span>
###xml 1763 1768 <span type="species:ncbi:4932">yeast</span>
###xml 1776 1783 <span type="species:ncbi:9606">patient</span>
###xml 1987 1992 <span type="species:ncbi:9606">human</span>
We next determined if the restoration of function we observed in S. cerevisiae could also occur in mammalian cells. To test this, we examined the effect of proteasome inhibitors on mammalian cells expressing mutant human CBS protein. We obtained four primary fibroblast lines and one EBV transformed lymphoblastoid line from five patients with CBS deficiency. Four of the five lines were from patients that were homozygous for a particular mutation (I278T, T353M, T262M, G307S), while one line was from a compound heterozygote (A114V/E302K). We then examined both steady state CBS protein and CBS enzyme activity in untreated and in cells treated with the proteasome inhibitor MG132 (Figure 4A). MG132 was used in these experiments because it was found to be a more potent inducer of Hsp70 than bortezomib for these cells (Figure S7). In the absence of drug, three of the five lines (I278T, T253M, and A114V/E302K) had undetectable levels of CBS protein and all five lines had <1% enzyme activity compared to a control primary human fibroblast line. Addition of MG132 resulted in restoration of steady-state CBS to wild-type levels in all five lines and caused a dramatic increase in enzyme activity (over 100-fold increase to 28 to 66% of wt CBS) in three of the five lines (I278T, T353M, and T262M). Interestingly, the increase in enzyme activity in the T262M cells was not associated with increased T262M protein levels, again suggesting that the rescuing effect of proteasome inhibitors is not due to inhibition of mutant protein degradation. Consistent with this idea, we found that MG132 resulted in a two-fold increase in Hsp70 (Figure 4A). With one exception, we note concordance in the behavior of mutants that were rescuable by proteasome inhibition in yeast and in patient fibroblasts. It is possible that the lack of rescue observed in the A114V allele may have to do with the cell line also having the E320K allele as well. In total, these results indicate that exposure of human cells to proteasome inhibitors can rescue enzymatic activity from several missense mutant CBS proteins.
###end p 35
###begin title 36
Functional rescue of mutant CBS by proteosome inhibitors in mammalian cells.
###end title 36
###begin p 37
###xml 532 535 528 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 520 535 516 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 554 557 550 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 542 557 538 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 1053 1055 1045 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/</sup>
###xml 1050 1055 1042 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cbs<sup>&#8722;/</sup></italic>
###xml 1055 1056 1047 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1137 1140 1129 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1125 1140 1117 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>+/&#8722;</sup></italic>
###xml 1250 1253 1242 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1238 1253 1230 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 42 49 <span type="species:ncbi:9606">patient</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
###xml 732 736 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">Mice</span>
###xml 1073 1078 <span type="species:ncbi:9606">human</span>
###xml 1253 1257 <span type="species:ncbi:10090">mice</span>
###xml 1306 1311 <span type="species:ncbi:10090">mouse</span>
(A) Restoration of CBS enzyme activity in patient fibroblasts. Primary fibroblast cells expressing the indicated CBS allele were grown to 80% confluency at which time MG132 (18 microM) was added. After seven hours protein was harvested and Hsp70, CBS, and actin protein levels were measured by immunoblot. CBS activity was measured and activity is expressed as nmole cystathionine formed/mg protein-hr. Note that the G307S cell line is a transformed lymphoid cell line. (B) Effect of intravenous bortezomib treatment on Tg-I278T Cbs-/- mice. Tg-I278T Cbs-/- mice were kept on zinc water for 10 days to induce transgene expression and then either injected with bortezomib (30 microg) or saline by tail vein injection. After 17 hours mice were sacrificed and tissues harvested. Immunoblot analysis of CBS in liver and kidney extracts from bortezomib treated "B" and non-treated (NT) I278T mice. Actin was used as loading control. CBS activity was measured and activity is expressed as nmole cystathionine formed/mg protein-hr. Mice labeled "No Tg" are Cbs-/- animals lacking human CBS. Lane labeled "C" contains extract from a Tg-I278T Cbs+/- animal. Bar graph shows Liver CBS activity in bortezomib treated (n = 4) and non-treated (n = 4) Tg-I278T Cbs-/-mice was compared with CBS activity in a non-treated mouse containing normal hCBS. Statistical significance was calculated by t test. Results are represented in terms of mean+/-SE. *P<0.05.
###end p 37
###begin title 38
###xml 68 71 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 56 71 56 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Increased CBS activity and lower plasma homocysteine in Tg-I278T Cbs-/- mouse treated with bortezomib
###end title 38
###begin p 39
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 82 97 82 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 155 158 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CBS</italic>
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Wang1">[23]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Chen1">[24]</xref>
###xml 392 399 392 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 564 567 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 552 567 548 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 824 833 820 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g004">Figure 4B</xref>
###xml 1042 1051 1038 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g004">Figure 4B</xref>
###xml 1153 1162 1149 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000807-g004">Figure 4B</xref>
###xml 1434 1443 1430 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s008">Figure S8</xref>
###xml 1559 1568 1555 1564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000807.s008">Figure S8</xref>
###xml 1628 1635 1624 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
###xml 179 184 <span type="species:ncbi:9606">human</span>
###xml 284 289 <span type="species:ncbi:9606">human</span>
###xml 313 318 <span type="species:ncbi:10090">mouse</span>
###xml 1031 1036 <span type="species:ncbi:9606">human</span>
Previously we had developed a mouse model for homocystinuria caused by I278T CBS (Tg-I278T Cbs-/-). This mouse contains a homozygous deletion of the mouse CBS gene, and expresses human I278T CBS under control of a zinc-inducible promoter [23]. In this animal it was demonstrated that human I278T CBS expressed in mouse liver had minimal enzyme activity [24]. To test the effect of bortezomib in vivo, we induced I278T expression by addition of zinc to the drinking water, and after one week injected 30 microg of bortezomib into the tail veins of four Tg-I278T Cbs-/- animals. After 17 hours, serum, liver and kidney were then harvested and analyzed. Examination of steady state CBS protein indicates that bortezomib greatly increased the amount of liver I278T protein and Hsp70 protein compared to a mock-injected control (Figure 4B). In addition, CBS enzyme activity increased on average 4.3-fold in the livers of treated animals compared to untreated controls, to about 18.7% of that found in an animal that expresses wild-type human CBS (Figure 4B). We also observed increased enzyme activity in kidney extracts in two of the four injected animals (Figure 4B). Interestingly, the kidney does not show significantly increased steady-state I278T protein, indicating that the increased enzyme activity is due entirely to increased enzyme specific activity. Bortezomib treatment resulted in a 46% decrease in tHcy in serum, (p<0.05) (Figure S8). Bortezomib also resulted in a 28% decrease in serum methionine, although this was not statistically significant (Figure S8). These results indicate that bortezomib can decrease tHcy in vivo by increasing residual I278T enzyme activity.
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 206 219 206 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S. cerevisiae</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP26</italic>
###xml 167 172 <span type="species:ncbi:9606">human</span>
###xml 206 219 <span type="species:ncbi:4932">S. cerevisiae</span>
In the work described here, we have shown that it is possible to restore substantial amount of functional activity to a large percentage of missense mutant alleles of human CBS, p53, and MTHFR expressed in S. cerevisiae by treatments that cause Hsp70 induction. These treatments include addition of ethanol or proteosome inhibitor to the media, or deletion of the small heat shock protein HSP26. At least one of these treatments was able to dramatically increase enzyme or transcriptional activity in 17/18 (94%) mutant CBS proteins, 19/25 mutant p53 proteins (76%), and 1/2 mutant MTHFR proteins (50%). Interestingly, different types of response to the different rescuing treatments were observed. Some mutants were rescued by all three treatments (e.g. I278T CBS), some by two of three treatments (e.g. T262M CBS), while others only responded to a single treatment (e.g. G307S CBS). These differences are probably not due to differential Hsp70 induction, as all three treatments result in similar levels of induction. We speculate that each of these different treatments may have unique effects on other molecular chaperones and that each treatment may produce a unique intracellular folding milieu. With regards to CBS mutants, we found that both pyridoxine responsive mutants (e.g. I278T) and non-responsive mutants (e.g. G307S) could be rescued.
###end p 41
###begin p 42
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-DePristo1">[25]</xref>
###xml 724 727 716 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Bross1">[2]</xref>
###xml 1237 1241 1229 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Meier1">[26]</xref>
Our findings support the view that most missense mutations primarily affect protein folding, as opposed to altering critical residues involved in specific catalytic or interaction sites. This agrees with biophysical studies of protein folding. As stated by DePristo et al. [25] "The overwhelming conclusion from 20 years of mutation studies on protein stability is that most amino-acid replacements, at all sites in a protein result in large effects on DeltaG relative to the observed range of DeltaG values themselves." It is also possible that in multi-domain proteins like CBS, mutations affect protein folding by trapping the protein in a non functional intermediate state due to the existence of a high kinetic barrier [2]. Therefore, a possible explanation for the effectiveness of chaperone manipulation is that chaperone complex either helps mutant proteins overcome rate-limiting kinetic constraints in the folding process or brings the trapped intermediate back to a folding competent state. Interestingly, in CBS, only one mutation, G116R, was not rescuable by any treatment. This mutation is located only three residues away from the lysine (K119) that binds the active site pyridoxal phosphate at the base of an alpha helix [26]. Thus this change may be an example of a mutation that affects a key catalytic-site in the protein.
###end p 42
###begin p 43
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 815 819 811 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Mu1">[27]</xref>
###xml 1005 1009 1001 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Kieran1">[28]</xref>
###xml 41 46 <span type="species:ncbi:4932">yeast</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 915 919 <span type="species:ncbi:10090">mice</span>
Our results also show that this is not a yeast-specific phenomenon. We were able to restore function to three of six mutant alleles present in fibroblast cells from CBS deficient patients by treatment with the proteasome inhibitor MG-132. In addition, we showed that a 4.3-fold increase in CBS activity could be achieved with a single injection of bortezomib into mice expressing I278T CBS. Consistent with our findings, Mu et al. showed that MG-132 could increase residual glucocerebrosidase enzyme activity four-fold in cell lines containing the L444P variant associated with Gaucher disease, and that a combination of MG-132 and a chemical chaperone, 2-Acetamido-2-deoxynojirimycin, could increase residual activity five-fold in cells containing the Tay-Sachs disease causing alpha-hexosaminidase G269S mutation [27]. In addition, the Hsp70-inducing drug arimoclomol was reported to delay disease progression in mice expressing a SOD1 mutant in which glycine is substituted with alanine at position 93 [28].
###end p 43
###begin p 44
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Gilardini1">[29]</xref>
###xml 908 912 908 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Jagannath1">[30]</xref>
###xml 1113 1117 1113 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Solit1">[31]</xref>
###xml 1118 1122 1118 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Cudkowicz1">[32]</xref>
###xml 1201 1209 1201 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 1041 1047 <span type="species:ncbi:9606">humans</span>
Taken together, these findings suggest that treatment with proteasome inhibitors and other Hsp70 inducers may be beneficial to individuals with severe genetic diseases caused by missense mutation. One potential concern with drugs that manipulate the molecular chaperone environment is they may have potential adverse effects on the normal proteome, and thus create side effects that would preclude their use as drugs. While this is a possibility, it should be noted that Bortezomib is already an FDA approved drug that is used to treat multiple myeloma. The major noted toxicity is peripheral neuropathy [29]. However, it is unknown if the levels of Bortezomib used to induce changes in the chaperone environment would need to be as high as those used in chemotherapy. Furthermore, there is another proteasome inhibitor in clinical trials (PR-171) that does not exhibit a strong peripheral neuropathy effect [30]. In addition, there are at least two other drugs that are known Hsp70 inducers that have undergone successful phase I trials in humans including 17-allylamino-17-demethoxygeldanamycin and arimoclomol [31],[32]. Therefore, while there may be some risk in this approach, there is no reason a priori to believe that the benefits of restoring function to a mutant protein would not out weigh the potential side effects.
###end p 44
###begin p 45
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Soussi1">[33]</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Bykov1">[34]</xref>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Bykov2">[35]</xref>
###xml 724 726 724 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 754 758 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Adams1">[36]</xref>
###xml 207 212 <span type="species:ncbi:9606">human</span>
In addition to germline genetic diseases, the work described here may have relevance to the treatment of somatic genetic diseases such as cancer. Mutations in p53 are the most frequent genetic alteration in human cancer, and loss of p53 function is critical for tumorigenesis [33]. Several pharmacologic chaperones that restore function to mutant p53 protein have been identified and these have been shown to effectively induce apoptosis in certain cells that express mutant p53 [34],[35]. Our findings suggest that proteasome inhibitors may also effectively restore function to certain p53 alleles. Although bortezomib has been shown to inhibit cell growth and cause apoptosis in a large number of cancer cell lines, the IC50 concentrations vary widely [36]. No systematic study of the relationship between bortezomib sensitivity and the p53 status of tumor cells has been reported.
###end p 45
###begin p 46
###xml 123 128 <span type="species:ncbi:9606">human</span>
In summary, the data reported here shows that the functional effects of a majority of missense mutations in at least three human genes can be reversed by treatments that alter the intracellular molecular chaperone environment. Based on these results, we suggest that drugs that effect the intracellular chaperone environment may be useful in the treatment of a number of genetic diseases caused by missense mutations.
###end p 46
###begin title 47
Materials and Methods
###end title 47
###begin title 48
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast strains, plasmids, growth, and drug treatment
###end title 48
###begin p 49
###xml 26 50 22 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">leu2 ura3 ade2 trp1 cys4</italic>
###xml 52 56 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEU2</italic>
###xml 64 113 60 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945; leu2 ura3 ade2 trp1 cys4::LEU2 hsp26::KanMX</italic>
###xml 130 154 118 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">leu2 ura3 ade2 trp1 cys4</italic>
###xml 156 165 144 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEU2 ssa2</italic>
###xml 167 172 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KanMX</italic>
###xml 213 217 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 218 222 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Kruger2">[37]</xref>
###xml 245 293 233 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATa ade2-1 leu2-3,112 trp1-1 his-11,15 can1-100</italic>
###xml 295 325 283 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ura3-1 URA3 3XRGC::pCYC1::ADE2</italic>
###xml 362 366 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Flaman1">[21]</xref>
###xml 388 398 376 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp26&#916;</italic>
###xml 413 422 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ssa2&#916;</italic>
###xml 440 451 420 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp104&#916;</italic>
###xml 561 565 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 601 612 577 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATa ade2-1</italic>
###xml 614 622 590 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">can1-100</italic>
###xml 624 638 600 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ura3 leu2 trp1</italic>
###xml 640 644 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">his3</italic>
###xml 646 667 622 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trp1 met11&#916;::TRP1</italic>
###xml 705 709 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Shan1">[22]</xref>
###xml 840 844 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Kruger3">[38]</xref>
###xml 845 849 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Shan2">[39]</xref>
###xml 941 945 913 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Flaman1">[21]</xref>
###xml 1007 1011 979 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TaqI</italic>
###xml 1512 1516 1475 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 1748 1751 1707 1710 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 1928 1931 1881 1884 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 14 18 <span type="species:ncbi:4932">WY35</span>
###xml 224 229 <span type="species:ncbi:4932">Yeast</span>
###xml 751 756 <span type="species:ncbi:9606">human</span>
###xml 1682 1687 <span type="species:ncbi:4932">yeast</span>
Yeast strains WY35 (alpha leu2 ura3 ade2 trp1 cys4::LEU2), LS1 (alpha leu2 ura3 ade2 trp1 cys4::LEU2 hsp26::KanMX) and LS3 (alpha leu2 ura3 ade2 trp1 cys4::LEU2 ssa2::KanMX) were generated as previously described [14],[37]. Yeast strain yIG397 (MATa ade2-1 leu2-3,112 trp1-1 his-11,15 can1-100, ura3-1 URA3 3XRGC::pCYC1::ADE2) was obtained from Dr. Richard Iggo [21]. Strains LS3 (yIG397+hsp26Delta), LS4 (yIG397+ssa2Delta) and LS5 (yIG397+hsp104Delta) were derived from this strain by transformation with appropriate deletion cassettes as previously described [14]. The MTHFR tester strain, XSY3-1a (MATa ade2-1, can1-100, ura3 leu2 trp1, his3, trp1 met11Delta::TRP1) was created as previously described [22]. Plasmids expressing wild-type or mutant human CBS proteins were created by site-directed mutagenesis and gap-repair as described [38],[39]. The plasmids expressing mutant p53 alleles were constructed using gap repair with pRDI-22 [21]. Additional p53 mutants were generated by amplification with TaqI polymerase, followed by gap-repair and subsequent screening on SC-ade media for non-functional alleles. Ninety-six clones were then isolated and sequenced. Twenty-three of these clones contained a single missense mutation and were used for the studies described here. Bortezomib (Velcadetrade mark, Millennium Pharmaceuticals, Inc) was obtained from the Fox Chase Cancer Center outpatient clinic. Synthetic complete media lacking cysteine (SC-Cys) and (SC-Cys+G418) were made as previously described [14]. SC+Cys media were made by adding glutathione to the indicated SC media at a final concentration of 30 microg/ml. All other chemicals were purchased from Sigma. For yeast cell growth assays, saturated cultures were diluted to an OD600 of 0.05 and treated with bortezomib in standard 15-ml borosilicate tubes containing 3 ml of media. Cells were then grown at 30degreesC with rotating aeration. After 24 hours OD600 was determined using a Milton Roy Spectronic 601 spectrophotometer (Ivyland, PA).
###end p 49
###begin title 50
Cell lines and drug treatment
###end title 50
###begin p 51
###xml 45 49 45 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Tang1">[40]</xref>
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Tang2">[41]</xref>
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Moat1">[42]</xref>
###xml 121 125 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-deFranchis1">[43]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Hu1">[44]</xref>
###xml 353 354 353 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cell lines used in this study were: WS1 (WT) [40], F5889 (I278T/I278T) [41], 382 (T262M/T262M ) [42], 2242 (A114V/E302K) [43], 3161 (T353M/T353M, JPK unpublished), 3079 (G307S/G307S) [44]. Fibroblasts and EBV transformed lymphoid cells were grown in MEM or RPMI medium supplemented with 15% FBS along with appropriate antibiotics, respectively, in 5% CO2 at 37degreesC. MG132 was purchased from Peptide International (product number, IZL-3175v). MG132 or bortezomib was added to cells when they reached 80% confluency and after seven hours of exposure, the MG132 containing media was discarded, cells were rinsed with PBS, and then harvested for protein extraction.
###end p 51
###begin title 52
Extract preparation and immunoblot analysis
###end title 52
###begin p 53
###xml 37 40 37 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Shan3">[45]</xref>
###xml 734 738 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 1227 1231 1215 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 1662 1666 1650 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Singh1">[14]</xref>
###xml 10 15 <span type="species:ncbi:4932">yeast</span>
###xml 123 128 <span type="species:ncbi:4932">Yeast</span>
###xml 446 452 <span type="species:ncbi:9913">bovine</span>
###xml 507 512 <span type="species:ncbi:4932">yeast</span>
###xml 755 760 <span type="species:ncbi:10090">mouse</span>
###xml 873 878 <span type="species:ncbi:10090">mouse</span>
###xml 924 927 <span type="species:ncbi:9685">cat</span>
###xml 971 976 <span type="species:ncbi:4932">Yeast</span>
###xml 994 999 <span type="species:ncbi:10090">mouse</span>
###xml 1076 1081 <span type="species:ncbi:9606">Human</span>
###xml 1237 1243 <span type="species:ncbi:9986">rabbit</span>
###xml 1257 1268 <span type="species:ncbi:3704">horseradish</span>
###xml 1296 1302 <span type="species:ncbi:9986">rabbit</span>
Saturated yeast were diluted to an OD600 of 0.05 and cells were harvested when OD was between 0.7 and 0.9 (mid-log phase). Yeast extracts were prepared by mechanical lysis as described previously [45]. Total mammalian protein extracts were prepared using the mammalian protein extraction reagent obtained from Pierce, Rockford, IL (product # 78501). Protein concentration was determined by the Coomassie Blue protein assay reagent (Pierce) using bovine serum albumin as a standard. For immunoblot analysis, yeast extracts containing 20 microg or mammalian cell containing 50 microg of total protein were run on precast Tris-acetate gels (Bio-Rad) at 15 mA and transferred to polyvinylidene difluoride membrane as previously described [14]. Immunopurified mouse anti-CBS was purchased from ABNOVA (catalogue # H00000875-A01) and was used at 1/10,000 dilution. Anti-p53 is a mouse monoclonal anti-body obtained by Calbiochem (cat. #OP43) and was used at a 1/1000 dilution. Yeast Hsp70 monoclonal mouse serum was from AbCAM (catalogue # ab5439) and used at a dilution of 1/5000. Human Hsp70 monoclonal antibody (product # SPA-810D) was used at 1/1000 dilution. Alpha-Tubulin antibody used here is the same as described previously [14]. For rabbit antiserum, a horseradish peroxidase-conjugated anti-rabbit secondary anti-body was used at a 1/30,000 dilution (Jackson ImmunoResearch, West Grove, PA). Signal was detected by chemiluminescence using SuperSignal West Pico chemiluminescent substrate (Amersham Biosciences) and Chemigenius station (Syngene); signal was quantitated by Alpha Innotech software. Immunopreciptiations were performed as previously described [14].
###end p 53
###begin title 54
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse studies
###end title 54
###begin p 55
###xml 133 136 133 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 122 136 122 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-hCBS Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 153 156 153 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 141 156 141 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg-I278T Cbs<sup>&#8722;/&#8722;</sup></italic>
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Wang1">[23]</xref>
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Wang2">[46]</xref>
###xml 334 344 334 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ad libitum</italic>
###xml 600 604 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Wang2">[46]</xref>
###xml 684 688 680 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Gupta2">[47]</xref>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
All animal studies were reviewed and approved by the Fox Chase Cancer Center Institutional Animal Care and Use Committee. Tg-hCBS Cbs-/- and Tg-I278T Cbs-/- mice were generated as previously described [23],[46]. All mice were from C57BL6 strain background and were fed the rodent chow (Teklad 2018SX; Harlan Teklad, Madison, WI, USA) ad libitum. Adult mice (9-12 months old) were injected with 30 microl of bortezomib (1 mg/ml) via tail vein injection. After 17 hour, mice were sacrificed and liver, kidney and serum were extracted. Liver and kidney homogenates were prepared as previously described [46]. Western blotting was done under denaturing conditions as previously described [47].
###end p 55
###begin title 56
CBS activity and metabolite measurement
###end title 56
###begin p 57
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Gupta2">[47]</xref>
###xml 388 391 384 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000807-Gupta1">[8]</xref>
CBS activity was measured in 30 mg of crude dialyzed protein extracts of liver and kidney, using a Biochrom 30 amino acid analyzer (Biochrom, Cambridge, UK) as described previously [47]. One unit of activity is one microM of cystathionine formed per hour per milligram of protein. The same instrument was employed to measure total homocysteine (tHcy) and methionine in serum as described [8].
###end p 57
###begin title 58
Supporting Information
###end title 58
###begin p 59
###xml 79 88 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cys4&#916;</italic>
###xml 205 208 201 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
CBS protein levels in all mutants grown in the presence or absence of ethanol. Cys4Delta cells (Wy35) were grown in SC+CYS media either in the absence or presence of 4% ethanol. After strains reached an OD600approximately1.5, extracts were prepared and Western analysis was performed using CBS antibody.
###end p 59
###begin p 60
(0.28 MB PDF)
###end p 60
###begin p 61
Click here for additional data file.
###end p 61
###begin p 62
###xml 126 135 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cys4&#916;</italic>
###xml 155 174 151 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cys4&#916;hsp26&#916;</italic>
CBS protein levels in all mutants grown in the presence or absence of Hsp26. The indicated mutants were expressed in either a cys4Delta strain (Wy35) or a cys4Deltahsp26Delta strain were grown in SC+CYS media, extracts were prepared, and Western analysis was performed using CBS antibody.
###end p 62
###begin p 63
(0.40 MB PDF)
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin p 65
###xml 100 109 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cys4&#916;</italic>
###xml 129 148 125 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cys4&#916;hsp26&#916;</italic>
###xml 459 464 <span type="species:ncbi:9606">human</span>
Interaction of D376N and G307S CBS with Hsp26. (A) The indicated mutants were expressed in either a cys4Delta strain (Wy35) or a cys4Deltahsp26Delta (LS1) strain. Cells were grown in SC+CYS media, extracts were prepared, and Western analysis was performed using CBS, Hsp26, and alpha-tubulin anti-bodies. The CBS enzyme activity present in each extract is shown at the bottom (n = 3; standard deviation shown). (B) Lysates from cells expressing the indicated human CBS allele were prepared and subject to immunoprecipitation using Hsp26 directed anti-body. Immunocomplexes were then analyzed by Western blot with CBS anti-bodies. Lane labeled control is extract without IP.
###end p 65
###begin p 66
(0.19 MB PDF)
###end p 66
###begin p 67
Click here for additional data file.
###end p 67
###begin p 68
###xml 124 133 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cys4&#916;</italic>
CBS protein levels in all mutants grown in the presence or absence of bortezomib. The indicated mutants were expressed in a cys4Delta strain (Wy35) grown in SC+CYS media in the presence or absence of 50 microM bortezomib. After 24 hours, extracts were prepared and Western analysis was performed using CBS antibody.
###end p 68
###begin p 69
(0.70 MB PDF)
###end p 69
###begin p 70
Click here for additional data file.
###end p 70
###begin p 71
###xml 10 19 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ssa2&#916;</italic>
###xml 24 35 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp104&#916;</italic>
###xml 73 77 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSA2</italic>
###xml 81 90 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ssa2&#916;</italic>
###xml 273 276 261 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 282 288 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP104</italic>
###xml 292 303 280 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hsp104&#916;</italic>
###xml 486 489 470 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 91 96 <span type="species:ncbi:4932">yeast</span>
###xml 304 309 <span type="species:ncbi:4932">yeast</span>
Effect of ssa2Delta and hsp104Delta on ethanol rescue of mutant p53. (A) SSA2 or ssa2Delta yeast cells expressing the indicated p53 alleles were grown in either in the presence or absence of ethanol and assessed for growth in SC-ade-ura media after 24 hours by measuring OD600. (B) HSP104 or hsp104Delta yeast cells expressing the indicated p53 alleles were grown in either in the presence or absence of ethanol and assessed for growth in SC-ade-ura media after 24 hours by measuring OD600.
###end p 71
###begin p 72
(0.16 MB PDF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
###xml 94 99 <span type="species:ncbi:4932">yeast</span>
###xml 132 137 <span type="species:ncbi:9606">human</span>
Rescue of multiple mutant p53 by ethanol or bortezomib treatment. Stationary phase culture of yeast yIG397 expressing the indicated human p53 allele was diluted 1:1000 in SC-ade -ura media supplemented with either 4% ethanol or 50 microM bortezomib and grown at 30degreesC for 24 h. Growth was then determined by measuring OD at 600 nm.
###end p 74
###begin p 75
(0.07 MB PDF)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 524 526 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 28 33 <span type="species:ncbi:9606">human</span>
CBS protein and activity in human cells treated with bortezomib. (A) Primary fibroblast cells expressing the indicated CBS allele were grown to 80% confluency at which time Bortezomib (18 microM) was added. After seven hours protein was harvested and Hsp70, CBS, and actin protein levels were measured by immunoblot. (B) Comparison of Hsp70 induction in bortezomib vs. MG132 cells. Gels were scanned using imaging software (Alpha Innotech 2.0) and the average induction is shown. Error bars show standard deviation. P<2.0x10-5 (t-test, two-sided).
###end p 77
###begin p 78
(0.64 MB PDF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
Serum total homocysteine and methionine levels in Tg-I278T Cbs-/- animals treated with bortezomib. Error bars show standard deviation *P<0.05 (t-test, 2-sided).
###end p 80
###begin p 81
(0.05 MB PDF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
We acknowledge the contribution of the FCCC Laboratory Animal Facility and also thank Brian Trimble from the FCCC pharmacy for supplying us with leftover bortezomib. We thank Maureen Murphy for providing DNA containing TP53 mutations. We also thank Richard Morimoto for helpful discussion.
###end p 83
###begin title 84
References
###end title 84
###begin article-title 85
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Gene Mutation Database (HGMD): 2003 update.
###end article-title 85
###begin article-title 86
Protein misfolding and degradation in genetic diseases.
###end article-title 86
###begin article-title 87
Cystathionine beta-synthase deficiency in Georgia (USA): correlation of clinical and biochemical phenotype with genotype.
###end article-title 87
###begin article-title 88
The natural history of homocystinuria due to cystathionine beta-synthase deficiency.
###end article-title 88
###begin article-title 89
The natural history of vascular disease in homocystinuria and the effects of treatment.
###end article-title 89
###begin article-title 90
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy.
###end article-title 90
###begin article-title 91
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study.
###end article-title 91
###begin article-title 92
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia.
###end article-title 92
###begin article-title 93
Germline TP53 mutations and Li-Fraumeni syndrome.
###end article-title 93
###begin article-title 94
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations.
###end article-title 94
###begin article-title 95
p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
###end article-title 95
###begin article-title 96
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human gene mutation database at the institute of medical genetics at Cardiff.
###end article-title 96
###begin article-title 97
Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency.
###end article-title 97
###begin article-title 98
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 107 131 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional rescue of mutant human cystathionine beta-synthase by manipulation of Hsp26 and Hsp70 levels in Saccharomyces cerevisiae.
###end article-title 98
###begin article-title 99
Pathways of chaperone-mediated protein folding in the cytosol.
###end article-title 99
###begin article-title 100
Molecular chaperones in the cytosol: from nascent chain to folded protein.
###end article-title 100
###begin article-title 101
Cystathionine beta-synthase mutations in homocystinuria.
###end article-title 101
###begin article-title 102
###xml 117 141 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Proteasome inhibitors cause induction of heat shock proteins and trehalose, which together confer thermotolerance in Saccharomyces cerevisiae.
###end article-title 102
###begin article-title 103
Proteasome inhibitors lactacystin and MG132 inhibit the dephosphorylation of HSF1 after heat shock and suppress thermal induction of heat shock gene expression.
###end article-title 103
###begin article-title 104
Proteasome inhibitors in cancer therapy: lessons from the first decade.
###end article-title 104
###begin article-title 105
A simple p53 functional assay for screening cell lines, blood, and tumors.
###end article-title 105
###begin article-title 106
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 76 100 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Functional characterization of human methylenetetrahydrofolate reductase in Saccharomyces cerevisiae.
###end article-title 106
###begin article-title 107
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model.
###end article-title 107
###begin article-title 108
Contrasting behaviors of mutant cystathionine beta-synthase enzymes associated with pyridoxine response.
###end article-title 108
###begin article-title 109
Missense meanderings in sequence space: a biophysical view of protein evolution.
###end article-title 109
###begin article-title 110
###xml 13 18 <span type="species:ncbi:9606">human</span>
Structure of human cystathionine beta-synthase: a unique pyridoxal 5'-phosphate-dependent heme protein.
###end article-title 110
###begin article-title 111
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.
###end article-title 111
###begin article-title 112
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice.
###end article-title 112
###begin article-title 113
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
###end article-title 113
###begin article-title 114
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
###end article-title 114
###begin article-title 115
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
###end article-title 115
###begin article-title 116
###xml 31 36 <span type="species:ncbi:9606">human</span>
Shaping genetic alterations in human cancer: the p53 mutation paradigm.
###end article-title 116
###begin article-title 117
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
###end article-title 117
###begin article-title 118
Small molecules that reactivate mutant p53.
###end article-title 118
###begin article-title 119
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
###end article-title 119
###begin article-title 120
###xml 2 7 <span type="species:ncbi:4932">yeast</span>
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
###xml 123 128 <span type="species:ncbi:4932">yeast</span>
A yeast system for expression of human cystathionine beta-synthase: structual and functional conservation of the human and yeast genes.
###end article-title 120
###begin article-title 121
###xml 2 7 <span type="species:ncbi:4932">yeast</span>
###xml 59 64 <span type="species:ncbi:9606">human</span>
A yeast assay for functional detection of mutations in the human cystathionine beta-synthase gene.
###end article-title 121
###begin article-title 122
###xml 47 52 <span type="species:ncbi:4932">yeast</span>
Correction of disease-causing CBS mutations in yeast.
###end article-title 122
###begin article-title 123
Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth.
###end article-title 123
###begin article-title 124
The methionine salvage pathway compound 4-methylthio-2-oxobutanate causes apoptosis independent of down-regulation of ornithine decarboxylase.
###end article-title 124
###begin article-title 125
###xml 81 89 <span type="species:ncbi:9606">patients</span>
The molecular basis of cystathionine beta-synthase (CBS) deficiency in UK and US patients with homocystinuria.
###end article-title 125
###begin article-title 126
Four novel mutations in the cystathionine beta-synthase gene: effect of a second linked mutation on the severity of the homocystinuric phenotype.
###end article-title 126
###begin article-title 127
Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria.
###end article-title 127
###begin article-title 128
###xml 92 99 <span type="species:ncbi:9606">patient</span>
Mutations in the regulatory domain of cystathionine beta synthase can functionally suppress patient-derived mutations in cis.
###end article-title 128
###begin article-title 129
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice.
###end article-title 129
###begin article-title 130
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Cystathionine beta-synthase p.S466L mutation causes hyperhomocysteinemia in mice.
###end article-title 130
###begin p 131
The authors have declared that no competing interests exist.
###end p 131
###begin p 132
This work was supported by grants from the NIH (HL57299 and CA06927). This work was also supported by an appropriation from the Commonwealth of Pennsylvania. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 132

